HIV/AIDS Clinical Care: Meetings

Tenofovir Use Linked to Fracture Risk

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

As reported at IAS 2011, the effect size was small but still worrisome.

• By Paul E. Sax, MD
• August 15, 2011

Is It Time to Start Treating Acute HIV Infection?

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

Trial data presented at IAS 2011 demonstrate some virologic and immunologic benefit to starting antiretroviral therapy during acute HIV infection.

• By Charles B. Hicks, MD
• August 15, 2011

Not All WHO-Recommended First-Line Regimens Are Equal

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

The efficacy of tenofovir + 3TC + nevirapine is questionable, according to a systematic review presented at IAS 2011.

• By Charles B. Hicks, MD
• August 15, 2011

Maraviroc + Boosted Atazanavir for Treatment-Naive Patients?

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

In a small trial presented at IAS 2011, 75% of patients on this regimen achieved virologic suppression at 48 weeks, compared with 84% of those on tenofovir/FTC + boosted atazanavir.

• By Charles B. Hicks, MD
• August 15, 2011

Switching from Abacavir/3TC to Tenofovir/FTC Yields Favorable Outcomes in Stable Patients

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

Virologic failures are less common after the switch, according to data presented at IAS 2011.

• By Paul E. Sax, MD
• August 15, 2011

Lersivirine Almost As Good As Efavirenz — But Not Quite

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

In a phase II trial presented at IAS 2011, rates of virologic suppression were 79% in patients receiving lersivirine and 86% in those receiving efavirenz.

• By Paul E. Sax, MD
• August 15, 2011

Elvitegravir Noninferior to Raltegravir in Treatment-Experienced Patients

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

Data presented at IAS 2011 support using elvitegravir + a ritonavir-boosted protease inhibitor + a third active agent in HIV-infected patients who have virologic failure after receiving two or more antiretroviral drug classes.

• By Charles B. Hicks, MD
• August 15, 2011

Dolutegravir Phase II Trial Results Very Promising

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

In a 48-week analysis presented at IAS 2011, this once-daily integrase inhibitor was shown to be both safe and effective among treatment-naive patients.

• By Charles B. Hicks, MD
• August 15, 2011

Report from the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention

• HIV/AIDS Clinical Care
• Meeting Report
• Free Article

Our physician-editors highlight the most clinically relevant findings from the meeting in Rome.

• By Paul E. Sax, MD, and Charles B. Hicks, MD
• August 15, 2011

Do Boosted Protease Inhibitors Increase the Risk for Chronic Kidney Disease?

• HIV/AIDS Clinical Care
• Meeting Report
• Subscription Required

Use of ritonavir-boosted atazanavir and lopinavir/ritonavir emerged as risk factors in studies presented at IAS 2011.

• By Paul E. Sax, MD
• August 15, 2011